Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0012833 (dizziness)
 9,689 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Recurrent transient neurologic deficits were evaluated clinically in four patients. In three patients, the symptoms included recurrent transient homonymous hemianopia, episodic weakness and numbness of the left arm and leg, and recurrent sudden loss of speech and of strength in the right arm. In these three patients, the episodes were first thought to be transient ischemic attacks (TIAs). A fourth patient had repeated confusional spells, in which a recurrent musical theme excluded other thoughts. This was associated with dizziness and difficulty in naming. A partial complex seizure was thought responsible. In each of the cases the symptoms lasted less than 30 minutes and were not associated with loss of consciousness, headache, or stiff neck. Electroencephalogram (EEG), brain scan, lumbar puncture, and computed tomography (CT) scan were normal. In all patients, cerebral arteriography unexpectedly revealed an unruptured cerebral aneurysm. The locations of the aneurysms were appropriate to the symptoms, which remitted in the three patients treated surgically for the aneurysm. Although the pathophysiology is uncertain, an ischemic process may be implicated.
 ...
PMID:Unruptured cerebral aneurysms presenting as recurrent transient neurologic deficits. 718 33

The records of 37 patients with systemic lupus erythematosus (SLE) followed at The Children's Hospital of Philadelphia between 1968 and 1978 were reviewed for evidence of central nervous system (CNS) involvement. Criteria for CNS involvement included evidence of organic brain syndrome, electroencephalographic abnormalities with symptoms referable to CNS, or objective neurologic signs. Sixteen of 37 children had CNS involvement (43%). Thirteen patients had CNS involvement at the onset of SLE. Three patients had late onset CNS manifestations 1 to 2 years after the diagnosis of SLE. The most frequently observed symptoms were headache, behavior disorder, lethargy, diplopia, blurred vision, memory alteration, dizziness, and alteration of consciousness. The most frequently observed neurologic signs were seizures, cranial nerve palsy, ataxia, papilledema, nystagmus, meningitis, tremor, rigidity, cortical blindness, and coma. Neuropsychiatric manifestations included organic brain syndrome, functional psychosis, and personality disorder. Laboratory tests showed elevated cerebrospinal fluid opening pressure and protein, negative cultures, and abnormal electroencephalograms and computerized axial tomography scans. Fourteen of 16 children with CNS manifestations are alive. Thirteen had a mean IQ of 89 by the Wechsler Intelligence Tests. Twelve are in educational programs. One required long-term psychiatric care. A residual neurologic abnormality, a seizure disorder, was present in 3. CNS involvement with SLE in children carries a favorable prognosis.
 ...
PMID:Central nervous system involvement in childhood systemic lupus erythematosus. 731 16

"T's and B's" is the street name for the combination of pentazocine and tripelennamine. This combination of drugs has emerged as a major intravenous substitute for heroin in recent years, especially in the Midwest. 104 cases involving 82 patients over a 9-month period were seen at St. Elizabeth Medical Center in Dayton, Ohio. Abscesses and cellulitis were seen in 39% of cases. A characteristic drug reaction involved 38% of cases, and consisted of chest pain, agitation, anxiety, muscle spasms, dizziness, diaphoresis, and nausea as well as other symptoms. Seizures, syncope, and near-syncope were seen in 15% of cases, and a previously described pulmonary reaction involved 38% of cases, and consisted of chest pain syndrome was seen in 4% of the cases.
 ...
PMID:"T's and B's"-Midwestern heroin substitute. 731 93

An apparent case of carbamazepine-induced leukocytosis in a 26-year-old woman is presented. When admitted for psychiatric evaluation, the patient had been receiving carbamazepine for seizures for some time. A hemogram revealed a white blood cell (WBC) count of 21.2 x 10(3)/cu mm. Five days after the patient's medication was changed from carbamazepine (600 mg/day) to phenytoin (400 mg/day) and phenobarbital (120 mg/day), her WBC count was within normal range. When she experienced dizziness and ataxia, the phenytoin and phenobarbital were replaced with carbamazepine (600 mg/day). WBC counts performed 11 and 13 days after resumption of carbamazepine therapy again were significantly elevated. Other drugs administered during hospitalization included chlorpromazine, acetaminophen, and codeine. The possible causes of and pathophysiology of leukocytosis are reviewed. The changes in WBC that occurred with the rechallenge of carbamazepine indicate that the drug was the probable cause of the leukocytosis.
 ...
PMID:Carbamazepine-induced leukocytosis. 737 19

A 40-year-old man developed general malaise, dizziness and progressive headache 1 week after acute haemorrhagic conjunctivitis. Bizarre behaviour, confusion and adversive seizures occurred later. MRI showed haemorrhagic infarct in the bilateral basal ganglia and thalamus and abnormal signal density in the internal cerebral veins. Bilateral carotid angiography showed no filling of superior sagittal sinus and internal cerebral veins. With MRI, cerebral venous thrombosis can be suspected and diagnosed earlier than before, obviating any invasive investigation.
 ...
PMID:MRI in internal cerebral vein thrombosis: case note. 747 53

1125 inhabitants of Slavutich city where workers of the Chernobyl Atomic Power Station and their families live, have been electroencephalographically examined. The reasons for the medical check-up involved specific complaints of a headache, dizziness, nightmares, early waking up in the mornings and sometimes seizures. Disorders of the bioelectrical activity of paroxysmal nature were revealed in 286 cases (197 children of 3-17 years, 99 adults of 18-50 years). The epileptiform findings seem to be related to the ionising radiation. The latency for a high (single or repeated) dose may be short (or minimal), and for a long-term effect of small doses--3-6 years. The latency was more or less similar and depended on a number of biophysical factors for the majority of the examined inhabitants of Slavutich city: children as well as adults (including those who work at the Chernobyl Atomic Power Station).
 ...
PMID:[The epileptiform reactions of the human brain to prolonged exposure to low-dose ionizing radiation]. 753 Oct 70

This multicenter, open-label trial was designed to study the safety of intravenous (IV) sodium valproate in patients with epilepsy. All 318 patients (previously treated with antiepileptic drugs) were hospitalized for seizure control or anticipated seizures. The protocol allowed physicians to set the number of infusions and treatment duration. Adverse events, laboratory studies performed, and seizure activity were documented on case report forms. The patients' mean age was 34.4 years (range, 2-87 years). The most common reason for admission was lack of seizure control (235 patients, 185 of whom were admitted for video-electroencephalographic monitoring). The median dosage of valproate was 375 mg infused over 1 hour. The median number of doses was four, given over 2 days. In 54 patients (17%), transient adverse events were reported. The most frequent were headache, reaction at the injection site, and nausea (2.2% each); somnolence (1.9%); vomiting (1.6%); and dizziness and taste perversion (1.3% each). No persistent or severe hematologic or serum chemistry abnormalities were found. Vital signs were not significantly affected by the IV infusion of valproate. At the dosages and rates of administration studied, intravenous valproate appears to be safe and well tolerated.
 ...
PMID:Safety of intravenous valproate. 757 66

Tiagabine is a new antiepileptic drug which acts by a novel mechanism, inhibiting the reuptake of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) into neurons and glia. A double-blind, placebo-controlled, crossover trial was undertaken, based upon a response-dependent design. Ninety-four patients with complex partial seizures with or without secondary generalised tonic-clonic seizures were recruited into an open screening phase and tiagabine was added to their existing drug therapy in doses titrated to reduce seizure frequency by > or = 25% or to the limit of tolerance. Forty-six responders were subsequently randomised to a double-blind crossover trial in which tiagabine was compared with placebo. Forty-two patients completed the trial. A significant reduction in the frequency of complex partial and secondary generalised tonic clonic seizures was seen. Twenty-six percent had a reduction of > or = 50% in the frequency of their complex partial seizures, and of the 27 patients who also had secondary generalised tonic clonic seizures, 63% experienced a reduction of > or = 50%. No interactions with baseline antiepileptic drugs were detected and no serious adverse reactions occurred. The commonest adverse events were tiredness, dizziness and headache. We conclude that tiagabine has promising antiepileptic effects. Further trials are underway.
 ...
PMID:Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial. 764 74

Syncope accounts for approximately 1% to 6% of hospital admissions and 3% of emergency room visits. Syncope is defined as a sudden transient loss of consciousness associated with a loss of postural tone with spontaneous recovery. Patients should not require electrical or chemical cardioversion to regain consciousness. Syncope must be clinically differentiated from other states of altered consciousness, such as dizziness, vertigo, seizures, coma, and nacrolepsy.
 ...
PMID:Workup and management of patients with syncope. 767 89

Felbamate is currently being developed as an antiepileptic agent. Although its mechanism of action has yet to be fully elucidated, felbamate appears to inhibit both the spread of seizures and increase seizure threshold in animal models. Data available in the clinical setting provide evidence that, at doses of up to 3600 mg/day as an adjunct to existing antiepileptic therapy or as monotherapy following substitution for other medications, the drug reduces the frequency of partial onset seizures in adult patients refractory to conventional antiepileptic treatments. Felbamate is also effective in the treatment of Lennox-Gastaut syndrome in children, a severe epilepsy which is usually refractory to antiepileptic agents. The effect of felbamate in the treatment of generalised tonic-clonic seizures in adults with partial onset seizures which are secondarily generalised is promising but requires clarification in large-scale trials. The most common adverse effects occurring during administration of felbamate are mild to moderate gastrointestinal (nausea, vomiting and anorexia) and central nervous system (headache, somnolence, diplopia, dizziness and insomnia) disturbances. Drug interactions with other antiepileptic agents may prove problematic in terms of adverse effects. Thus, at this stage of its development, the antiepileptic efficacy of felbamate in treatment-refractory patients with partial onset seizures and Lennox-Gastaut syndrome has been proven but efficacy in generalised tonic-clonic seizures requires further substantiation in large well controlled and well designed clinical trials. In addition, a more comprehensive base of comparative clinical trials data is necessary to further clarify issues of relative efficacy and tolerability compared with other antiepileptic agents. The clinical implications of the drug interactions associated with felbamate also require more detailed investigation. These data will be awaited with interest and when available will help to place felbamate in perspective in the management of epilepsy.
 ...
PMID:Felbamate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy. 769 93


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>